Association of CSF Aβ38 Levels With Risk of Alzheimer Disease-Related Decline.
Nicholas Cullen, Shorena Janelidze, Sebastian Palmqvist...
https://pubmed.ncbi.nlm.nih.gov/34937781/Actively Recruiting
Led by Skane University Hospital · Updated on 2026-04-06
2950
Participants Needed
2
Research Sites
N/A
Total Duration
Researchers are investigating dementia and related neurodegenerative diseases, including Alzheimers disease, Parkinsons disease, and other dementias, through the Swedish BioFINDER 2 Study. Building on the earlier BioFINDER 1 study, this research aims to improve early and accurate diagnosis using advanced imaging and biomarker techniques. The study also seeks to understand disease mechanisms, develop pathology-based classifications, and monitor the effects of new therapies in people with different stages of cognitive impairment and dementia. The study involves multiple participant groups ranging from cognitively healthy younger adults to patients with mild cognitive impairment or dementia due to Alzheimers and other neurodegenerative diseases. Participants undergo brain imaging including PET scans for amyloid and tau proteins, MRI, and DaTSCAN for certain parkinsonian disorders. Biomarker analyses are conducted from cerebrospinal fluid and blood samples. Follow-up assessments occur regularly over periods from 2 to 8 years depending on the cohort, with repeated cognitive, neurological, psychiatric, motor function tests, and imaging at defined intervals. During the study, participants complete detailed cognitive testing, motor assessments, and questionnaires addressing memory, attention, behavioral symptoms, mood, quality of life, and sleep. Clinical diagnoses and cognitive decline are monitored annually or biennially. Safety and adherence are ensured by standardized sampling protocols and imaging procedures. The main outcomes include clinical diagnosis, dementia rating scales, and biomarker changes, supporting improved diagnosis and understanding of dementia progression in diverse populations.
CONDITIONS
The Swedish BioFINDER 2 Study
E
Erik Stomrud, MD, PhD
S
Sebastian Palmqvist, MD, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Skane University Hospital
Lead Sponsor
Lund University
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Baseline visit and repeated assessments over 2 to 8 years depending on cohort
Participants undergo comprehensive diagnostic assessments including cognitive testing, motor assessments, cerebrospinal fluid and blood sampling, MRI, and PET imaging to measure brain pathology and biomarkers.
1 baseline visit followed by visits every 1 to 2 years depending on cohort assignment
Duration - Up to 8 years depending on cohort
Participants are monitored with repeated clinical, cognitive, neurological, and psychiatric assessments, as well as biomarker and imaging follow-ups to track disease progression or stability.
Follow-up visits every 12 to 24 months for up to 8 years
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
5
Have more questions? Get in touch with our team for quick support
Nicholas Cullen, Shorena Janelidze, Sebastian Palmqvist...
https://pubmed.ncbi.nlm.nih.gov/34937781/Niklas Mattsson-Carlgren, Sebastian Palmqvist, Kanta Horie...
https://pubmed.ncbi.nlm.nih.gov/41864233/Skane University Hospital
Lead Sponsor
Lund University
Collaborating Sponsor